Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support
Kollmannsberger, C × Schleucher, N Rick, O Metzner, B Hartmann, JT Schöffski, Patrick Beyer, J Casper, J Sosada, M Schmoll, HJ Bohlke, I Meisner, C Kanz, L Bokemeyer, C #
European Journal of Cancer vol:39 issue:6 pages:775-782
The aim of this study was to identify treatment strategies and therapeutic or clinical factors that predict for response to salvage therapy and survival in patients with metastatic 'Indiana advanced' or International Germ-Cell Cancer Collaborative Group (IGCCCG) poor prognosis' germ cell cancer (GCT) failing first-line sequential high-dose chemotherapy plus autologous stem cell support (HD-CT). A total of 58 'poor prognosis' patients who had relapsed after HD-CT were identified within two large prospective German first-line HD-CT trials (n = 286) performed between March 1993 and March 2001. Salvage treatment consisted of the following: cisplatin-based conventional dose CTx resection (19/58; 33%), non-cisplatin based CTx (16/58; 28%) or salvage HD-CT (14/58; 24%) resection; resection (n = 3) and/or radiation (n = 5) only: 7 patients (12%); no specific therapy: 2 patients. 21 (39%) patients responded favourably (Complete Response (CR)/Partial Response (PR) marker-negative) to salvage therapy. The use of salvage HD-CT (2-year survival 48%; P = 0.03, the complete resection of residual masses (2-year survival 42%; P = 0.015) as well as a favourable response to salvage therapy (2-year survival: 31%, P = 0.014) were the only variables on univariate analysis associated with an improved survival. The estimated 2-year overall survival rate is 32% (95% Confidence Interval CI: 29-45%). Approximately 30% of patients relapsing after first-line HD-CT will survive > 2 years, particularly those patients who can be treated with a second HD-CT + and/or surgical resection. If feasible, complete surgical resection of residual tumours appears to be the most efficient treatment. (C) 2003 Published by Elsevier Science Ltd.